Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Infusion of Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

NCT06375161 is registered in ClinicalTrials.gov with Shanghai Tongji Hospital, Tongji University School of Medicine as lead sponsor.

NCT NCT06375161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06375161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Infusion of Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
December 11, 2023
Completion date
December 10, 2039
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell malignancies